Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMLXNASDAQ:INVANASDAQ:MNKDNASDAQ:TNGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMLXAmylyx Pharmaceuticals$4.83+0.8%$4.38$1.58▼$7.27$429.21M-0.61.21 million shs251,137 shsINVAInnoviva$19.39+1.4%$18.23$15.20▼$21.28$1.22B0.35639,642 shs161,191 shsMNKDMannKind$4.12+1.1%$4.68$4.05▼$7.63$1.25B1.142.37 million shs525,452 shsTNGXTango Therapeutics$2.34+20.4%$1.47$1.03▼$12.02$253.10M1.021.30 million shs5.79 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMLXAmylyx Pharmaceuticals+1.48%-11.79%-4.39%+51.58%+180.12%INVAInnoviva-0.16%+0.90%+4.03%+8.95%+23.04%MNKDMannKind-3.10%-2.40%-13.95%-22.18%-12.10%TNGXTango Therapeutics-5.37%+2.65%+30.20%-11.01%-71.68%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMLXAmylyx Pharmaceuticals3.2615 of 5 stars3.61.00.00.03.24.21.3INVAInnoviva4.4673 of 5 stars3.51.00.04.23.72.51.9MNKDMannKind3.0765 of 5 stars3.61.00.00.03.51.71.9TNGXTango Therapeutics2.1433 of 5 stars3.51.00.00.03.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMLXAmylyx Pharmaceuticals 3.13Buy$9.83103.76% UpsideINVAInnoviva 3.00Buy$55.00183.65% UpsideMNKDMannKind 3.25Buy$10.00143.01% UpsideTNGXTango Therapeutics 3.00Buy$12.20422.48% UpsideCurrent Analyst Ratings BreakdownLatest TNGX, MNKD, AMLX, and INVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025AMLXAmylyx PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$7.00 ➝ $8.005/9/2025AMLXAmylyx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $16.005/7/2025AMLXAmylyx PharmaceuticalsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$4.00 ➝ $10.005/6/2025AMLXAmylyx PharmaceuticalsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/14/2025TNGXTango TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.004/10/2025MNKDMannKindMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$12.004/9/2025MNKDMannKindMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/7/2025AMLXAmylyx PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Outperform$3.00 ➝ $7.003/7/2025INVAInnovivaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$55.003/5/2025AMLXAmylyx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMLXAmylyx Pharmaceuticals-$1.27M-338.20$0.88 per share5.51$6.42 per share0.75INVAInnoviva$369.84M3.29$3.75 per share5.17$10.66 per share1.82MNKDMannKind$297.60M4.20N/AN/A($0.91) per share-4.52TNGXTango Therapeutics$40.99M6.17N/AN/A$2.48 per share0.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMLXAmylyx Pharmaceuticals$49.27M-$3.11N/AN/AN/AN/A-36.97%-29.61%8/14/2025 (Estimated)INVAInnoviva$179.72M-$1.0128.0912.51N/A18.31%20.84%11.38%7/29/2025 (Estimated)MNKDMannKind-$11.94M$0.1058.9317.89N/A8.07%-17.74%8.68%8/6/2025 (Estimated)TNGXTango Therapeutics-$101.74M-$1.22N/AN/AN/A-284.42%-49.64%-32.00%8/6/2025 (Estimated)Latest TNGX, MNKD, AMLX, and INVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025TNGXTango Therapeutics-$0.34-$0.36-$0.02-$0.36$6.73 million$5.39 million5/8/2025Q1 2025AMLXAmylyx Pharmaceuticals-$0.45-$0.42+$0.03-$0.42N/AN/A5/8/2025Q1 2025MNKDMannKind$0.03$0.04+$0.01$0.04$75.86 million$78.35 million5/7/2025Q1 2025INVAInnovivaN/A$0.25N/A-$0.74N/A$88.63 million3/4/2025Q4 2024AMLXAmylyx Pharmaceuticals-$0.49-$0.55-$0.06-$0.55N/A($0.67) millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMLXAmylyx Pharmaceuticals$1.0221.05%N/AN/A N/AINVAInnovivaN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/ATNGXTango TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMLXAmylyx PharmaceuticalsN/A4.554.55INVAInnoviva0.381.791.64MNKDMannKindN/A4.544.17TNGXTango TherapeuticsN/A8.008.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMLXAmylyx Pharmaceuticals95.84%INVAInnoviva99.12%MNKDMannKind49.55%TNGXTango Therapeutics78.99%Insider OwnershipCompanyInsider OwnershipAMLXAmylyx Pharmaceuticals11.70%INVAInnoviva2.25%MNKDMannKind3.00%TNGXTango Therapeutics6.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMLXAmylyx Pharmaceuticals20089.14 million60.53 millionOptionableINVAInnoviva10062.78 million61.54 millionOptionableMNKDMannKind400303.93 million267.51 millionOptionableTNGXTango Therapeutics90108.39 million100.65 millionOptionableTNGX, MNKD, AMLX, and INVA HeadlinesRecent News About These CompaniesWoodline Partners LP Takes Position in Tango Therapeutics, Inc. (NASDAQ:TNGX)May 28 at 4:30 AM | marketbeat.comTango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare ConferenceMay 27 at 10:32 PM | finance.yahoo.comTango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare ConferenceMay 27 at 7:00 AM | globenewswire.comTango Therapeutics starts trial for brain cancer drugMay 23, 2025 | uk.investing.comTango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid TumorsMay 21, 2025 | globenewswire.com517,426 Shares in Tango Therapeutics, Inc. (NASDAQ:TNGX) Acquired by Jacobs Levy Equity Management Inc.May 19, 2025 | marketbeat.comQ2 EPS Estimate for Tango Therapeutics Increased by AnalystMay 17, 2025 | marketbeat.comDimensional Fund Advisors LP Purchases 302,087 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX)May 17, 2025 | marketbeat.comTango Therapeutics, Inc. (NASDAQ:TNGX) Just Reported Earnings, And Analysts Cut Their Target PriceMay 16, 2025 | finance.yahoo.comOrbimed Advisors LLC Takes Position in Tango Therapeutics, Inc. (NASDAQ:TNGX)May 15, 2025 | marketbeat.comTango Therapeutics (NASDAQ:TNGX) Posts Earnings Results, Misses Estimates By $0.02 EPSMay 14, 2025 | marketbeat.comTango Therapeutics Reports Q1 2025 Financial Results and Updates on TNG462 and Pipeline DevelopmentsMay 14, 2025 | nasdaq.comTango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business HighlightsMay 13, 2025 | finanznachrichten.deTango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business HighlightsMay 13, 2025 | finance.yahoo.comTango Therapeutics Extends Cash Runway Amid Clinical ProgressMay 13, 2025 | tipranks.comTango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Lags Revenue EstimatesMay 12, 2025 | zacks.comTango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business HighlightsMay 12, 2025 | globenewswire.com4,000,000 Shares in Tango Therapeutics, Inc. (NASDAQ:TNGX) Bought by Farallon Capital Management LLCMay 11, 2025 | marketbeat.comBalyasny Asset Management L.P. Has $10.13 Million Position in Tango Therapeutics, Inc. (NASDAQ:TNGX)May 11, 2025 | marketbeat.comTango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Rating of "Buy" by AnalystsMay 11, 2025 | marketbeat.comTango Therapeutics (TNGX) to Release Quarterly Earnings on MondayMay 7, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTNGX, MNKD, AMLX, and INVA Company DescriptionsAmylyx Pharmaceuticals NASDAQ:AMLX$4.83 +0.04 (+0.75%) As of 01:18 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Innoviva NASDAQ:INVA$19.39 +0.27 (+1.41%) As of 01:18 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.MannKind NASDAQ:MNKD$4.12 +0.05 (+1.11%) As of 01:18 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.Tango Therapeutics NASDAQ:TNGX$2.34 +0.40 (+20.36%) As of 01:17 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
